MIRena for treatment of Endometrial Neoplastic Abnormalities (MIRENA)
Research type
Research Study
Full title
MIRena for treatment of Endometrial Neoplastic Abnormalities (MIRENA)
IRAS ID
148213
Contact name
Emma J Crosbie
Contact email
Sponsor organisation
Manchester University NHS Foundation Trust
Research summary
Womb cancer has become the most common cancer of the reproductive tract in British women. Atypical endometrial hyperplasia is a premalignant condition that progresses to womb cancer in up to 50% of cases. Obese women are at increased risk of womb cancer and are also more likely to die from it. The recent obesity epidemic means that more women than ever before are developing the disease. Surgery is the mainstay of treatment for both hyperplasia and womb cancer, but this can be challenging in obese or elderly women and also renders a woman infertile. Treatment with the hormone progestin, either given by tablet or directly into the womb (Mirena coil) is increasingly being used to treat women not fit for surgery or where a woman wishes to retain her fertility. Currently we do not know which women will respond to progestin treatment, and who will not. This study aims to determine how microscopic changes in the tissue or blood of patients with endometrial hyperplasia or cancer (endometrial cancer biomarkers) change with progestin treatment and whether certain biomarkers can predict response.
REC name
North West - Haydock Research Ethics Committee
REC reference
14/NW/0056
Date of REC Opinion
7 Mar 2014
REC opinion
Further Information Favourable Opinion